Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) - Stock analysts at HC Wainwright lifted their Q1 2025 earnings estimates for Assembly Biosciences in a note issued to investors on Monday, March 24th. HC Wainwright analyst E. Arce now expects that the biopharmaceutical company will post earnings of ($1.54) per share for the quarter, up from their prior forecast of ($1.95). HC Wainwright has a "Neutral" rating on the stock. The consensus estimate for Assembly Biosciences' current full-year earnings is ($6.87) per share. HC Wainwright also issued estimates for Assembly Biosciences' Q2 2025 earnings at ($1.54) EPS, Q3 2025 earnings at ($1.64) EPS, Q4 2025 earnings at ($1.57) EPS, FY2025 earnings at ($6.29) EPS, FY2026 earnings at ($9.05) EPS, FY2027 earnings at ($12.07) EPS and FY2028 earnings at ($12.32) EPS.
Other equities research analysts also recently issued research reports about the company. StockNews.com downgraded Assembly Biosciences from a "buy" rating to a "hold" rating in a research report on Monday, March 24th. Guggenheim assumed coverage on shares of Assembly Biosciences in a report on Tuesday, March 25th. They issued a "buy" rating and a $31.00 price target on the stock.
Get Our Latest Research Report on Assembly Biosciences
Assembly Biosciences Stock Performance
Assembly Biosciences stock traded down $0.28 during midday trading on Wednesday, reaching $10.62. 12,009 shares of the stock were exchanged, compared to its average volume of 24,885. Assembly Biosciences has a 52 week low of $10.27 and a 52 week high of $19.93. The firm has a market cap of $79.68 million, a PE ratio of -1.58 and a beta of 0.62. The company's fifty day moving average is $12.55 and its 200-day moving average is $14.94.
Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last posted its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, topping the consensus estimate of ($1.75) by $0.18. The firm had revenue of $7.36 million during the quarter, compared to the consensus estimate of $7.05 million. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%.
Institutional Trading of Assembly Biosciences
Hedge funds have recently made changes to their positions in the stock. Gilead Sciences Inc. bought a new stake in Assembly Biosciences in the fourth quarter worth $34,865,000. Renaissance Technologies LLC grew its position in Assembly Biosciences by 44.3% during the 4th quarter. Renaissance Technologies LLC now owns 94,711 shares of the biopharmaceutical company's stock valued at $1,495,000 after purchasing an additional 29,087 shares during the last quarter. Peapod Lane Capital LLC bought a new stake in Assembly Biosciences during the 4th quarter valued at about $994,000. B Group Inc. purchased a new position in Assembly Biosciences in the fourth quarter worth about $799,000. Finally, Monimus Capital Management LP purchased a new position in Assembly Biosciences in the fourth quarter worth about $664,000. 19.92% of the stock is owned by institutional investors.
Insiders Place Their Bets
In other news, Director Michael Houghton acquired 3,202 shares of the stock in a transaction on Monday, December 30th. The stock was acquired at an average price of $15.61 per share, with a total value of $49,983.22. Following the completion of the transaction, the director now owns 3,202 shares of the company's stock, valued at $49,983.22. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 5.10% of the company's stock.
Assembly Biosciences Company Profile
(
Get Free Report)
Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
Further Reading
Before you consider Assembly Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assembly Biosciences wasn't on the list.
While Assembly Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
